Online citations, reference lists, and bibliographies.
← Back to Search

Translational Advances In Pleural Malignancies

Georgios T. Stathopoulos
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Pleural malignancies, including primary malignant pleural mesothelioma and secondary pleural metastasis of various tumours resulting in malignant pleural effusion, are frequent and lethal diseases that deserve devoted translational research efforts for improvements to be introduced to the clinic. This paper highlights select clinical advances that have been accomplished recently and that are based on preclinical research on pleural malignancies. Examples are the establishment of folate antimetabolites in mesothelioma treatment, the use of PET in mesothelioma management and the discovery of mesothelin as a marker of mesothelioma. In addition to established translational advances, this text focuses on recent research findings that are anticipated to impact clinical pleural oncology in the near future. Such progress has been substantial, including the development of a genetic mouse model of mesothelioma and of transplantable models of pleural malignancies in immunocompetent hosts, the deployment of stereological and imaging methods for integral assessment of pleural tumour burden, as well as the discovery of the therapeutic potential of aminobiphosphonates, histone deacetylase inhibitors and ribonucleases against malignant pleural disease. Finally, key obstacles to overcome towards a more rapid advancement of translational research in pleural malignancies are outlined. These include the dissection of cell‐autonomous and paracrine pathways of pleural tumour progression, the study of mesothelioma and malignant pleural effusion separately from other tumours at both the clinical and preclinical levels, and the expansion of tissue banks and consortia of clinical research of pleural malignancies.
This paper references
10.1200/JCO.2009.26.9944
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
Isolation of rare circulat
S Nagrath (2008)
10.2353/ajpath.2009.090400
Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.
A. Shukla (2009)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1038/gt.2010.87
AAVrh.10-mediated Genetic Delivery of Bevacizumab to the Pleura to Provide Local Anti-VEGF to Suppress Growth of Metastatic Lung Tumors
M. Watanabe (2010)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Fluorescence in situ hybridiza
S Savic (2010)
10.1038/sj.bjc.6605814
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
J. D. Veltman (2010)
10.1186/1476-4598-9-56
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study
I. Psallidas (2009)
10.1183/09031936.00037310
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
10.1097/MCP.0b013e32833a233b
Risk reduction in pleural procedures: sonography, simulation and supervision
J. Wrightson (2010)
10.1038/nature06084
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a
P. Krimpenfort (2007)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1201/B13502-16
Experimental Models : pleural diseases other than mesothelioma
G. Stathopoulos (2008)
10.3322/caac.20073
Cancer Statistics, 2010
A. Jemal (2010)
Experimental models: pleural
GT Stathopoulos (2009)
A decision tree for differen
JM Porcel (2009)
10.1164/rccm.200804-616ED
Malignant pleural effusions: fixing the leaky faucet.
Y. Lee (2008)
10.1186/1471-2407-8-236
National Mesothelioma Virtual Bank: A standard based biospecimen and clinical data resource to enhance translational research
W. Amin (2008)
10.1177/1947601910375273
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.
C. Menges (2010)
Frequent epidermal growth factor
SG Wu (2009)
p 15 Ink 4 b is a critical tumour suppressor in the absence of p 16 Ink 4 a
MA López-Lago (2007)
10.1371/journal.pone.0003289
Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells
R. Carroll (2008)
10.1183/09031936.00090407
Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1α
C. Riganti (2008)
10.1158/0008-5472.CAN-09-3993
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
H. Pass (2010)
hsa - miR - 29 c * is linked to the prognosis of malignant pleural mesothelioma
HI Pass (2010)
The utility of multi-detector
KW Kim (2007)
10.1200/JCO.2007.12.5294
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
A. Bottomley (2007)
10.1158/0008-5472.CAN-09-1073
Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.
B. Christensen (2009)
10.1378/CHEST.128.2.684
Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions.
M. S. Paschoalini (2005)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1089/hum.2009.088
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
V. Saloura (2010)
10.1378/chest.09-0884
Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
M. Metintas (2010)
10.1038/mt.2009.309
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.
D. Sterman (2010)
10.1016/j.ejim.2007.09.014
Prognostic significance of pleural fluid data in patients with malignant effusion.
S. Bielsa (2008)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1371/journal.pone.0006554
Genome-Wide Profile of Pleural Mesothelioma versus Parietal and Visceral Pleura: The Emerging Gene Portrait of the Mesothelioma Phenotype
O. D. Røe (2009)
10.1038/nature06385
Isolation of rare circulating tumour cells in cancer patients by microchip technology
S. Nagrath (2007)
Nuclear Factor-kB activation affects tumor progression in a mouse model of malignant pleural effusion
GT Stathopoulos (2006)
10.1164/AJRCCM.179.9.851A
Screening for malignant mesothelioma--looking for the holy grail.
B. Grigoriu (2009)
Polarization of tumorassociated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2
ZG Fridlender (2009)
: JCOG 9515
M Suzuki (2007)
10.1136/thx.2007.077958
Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis
Q-L Liang (2007)
10.1073/pnas.0808816106
Activated TNF-α/NF-κB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice
D. Altomare (2009)
10.1111/j.1365-2559.2009.03322.x
Caveolin‐1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma
V. Amatya (2009)
10.1158/1078-0432.CCR-07-0536
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
A. Sartore-Bianchi (2007)
10.1158/1078-0432.CCR-08-2641
CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion
Xue-jun Qin (2009)
10.1097/MCP.0b013e32832af07c
Animal models of malignant pleural effusion
G. Stathopoulos (2009)
10.1038/sj.bjc.6605786
Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
S. Tsuji (2010)
Epigenetic profiles distinguish
Y Goto (2009)
10.1002/ijc.25002
An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S‐1 therapy
K. Yanagihara (2010)
10.1016/j.nucmedbio.2009.01.018
Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
A. Tsuji (2009)
10.1158/0008-5472.CAN-09-2326
CCL2 blockade augments cancer immunotherapy.
Z. Fridlender (2010)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
Guidelines of the ERS / ESTS for management of malignant pleural mesothelioma
A Scherpereel (2010)
10.1111/j.1349-7006.2009.01181.x
Malignant mesothelioma‐associated antigens recognized by tumor‐infiltrating B cells and the clinical significance of the antibody titers
Y. Shigematsu (2009)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
Identification of MCAM
S Bidlingmaier (2010)
Low-dose computed tomog
G Fasola (2009)
SEER data submission
S F Altekruse (1975)
10.1136/thx.45.2.81
Management of malignant pleural effusions.
M. Tattersall (1990)
10.1186/1471-2407-10-242
Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients
I. Raiko (2009)
10.1164/rccm.200710-1513OC
Zoledronic acid is effective against experimental malignant pleural effusion.
G. Stathopoulos (2008)
10.1136/thx.2008.100545
Thoracic ultrasound in the diagnosis of malignant pleural effusion
N. R. Qureshi (2008)
Soluble mesothelin-carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
P Wheatley-Price (2009)
10.1593/NEO.81480
The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.
C. Moschos (2009)
10.1016/s0272-2712(18)30563-8
Effusion cytology.
H. Ehya (1991)
Potential of dual time point
A Mavi (2010)
Prognostic significance
S Bielsa (2009)
10.1097/JTO.0b013e31811f4703
The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer
P. Postmus (2007)
10.1073/pnas.0712399105
Transcriptome sequencing of malignant pleural mesothelioma tumors
D. Sugarbaker (2008)
10.3816/CLC.2009.n.075
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
H. Wakelee (2009)
10.1007/s11307-009-0212-5
Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease
A. Mavi (2009)
10.1165/rcmb.2007-0460OC
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
S. Wilson (2008)
10.1158/0008-5472.CAN-08-2586
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome.
B. Christensen (2009)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1073/pnas.1006542107
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
H. Yang (2010)
An orthotopic
K Yanagihara (2009)
Soluble mesothelin-related
EK Park (2005)
Secretion of intelectin-1
S Tsuji (2007)
10.32388/i2tar4
The phase II trial.
R. Wittes (1985)
10.1097/JTO.0b013e31819c8661
Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma.
V. Velcheti (2009)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1183/09031936.00167407
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
S. Wu (2008)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
[Phase II study].
H. Niitani (1995)
High levels of tumor markers
S Bielsa (2008)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1111/j.1440-1843.2004.00566.x
Management of malignant pleural effusions
Y. Lee (2004)
10.1111/j.1440-1843.2007.01100.x
Pleurodesis: A novel experimental model
E. Marchi (2007)
10.1016/j.ccr.2008.01.030
A conditional mouse model for malignant mesothelioma.
J. Jongsma (2008)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1128/MCB.01578-08
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
M. López-Lago (2009)
10.1158/0008-5472.CAN-08-0969
Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway.
I. Graziani (2008)
Epithelial nuclear
GT Stathopoulos (2009)
10.1073/pnas.1001515107
Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays
A. Saliba (2010)
10.1158/1078-0432.CCR-05-0883
Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity
E. Suzuki (2005)
10.1164/rccm.200809-1522ST
An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure.
C. Hsia (2010)
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
10.1038/mt.2009.309
A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions.
D. Sterman (2010)
Global gene expression
S Crispi (2008)
10.1016/j.lungcan.2008.06.020
Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
R. Cui (2009)
EORTC-NCIC. Symptoms
A Bottomley (2009)
Phase I study of SS 1 P , a recombinant anti - mesothelin immunotoxin given as a bolus I . V . infusion to patients with mesothelin - expressing mesothelioma , ovarian , and pancreatic cancers
R Hassan (2007)
10.1158/0008-5472.CAN-08-0047
Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.
T. Fukazawa (2008)
10.1002/pmic.200800284
Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA‐15 in human malignant pleural mesothelioma cell lines
Y. Kuramitsu (2009)
10.1016/j.ejca.2009.04.028
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
J. Francart (2009)
10.1002/1097-4679(195201)8:1<42::AID-JCLP2270080110>3.0.CO;2-Q
The prognostic index.
F. Thorne (1952)
10.1016/j.ejim.2009.07.015
High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.
S. Singh (2009)
10.1016/j.ejrad.2009.04.061
The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer.
K. Kim (2010)
10.1016/S0140-6736(07)60708-9
Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study
J. Janssen (2007)
10.1073/pnas.0705316104
Epithelial NF-κB activation promotes urethane-induced lung carcinogenesis
G. Stathopoulos (2007)
10.1634/THEONCOLOGIST.12-10-1215
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
G. Fasola (2007)
10.1378/chest.09-1951
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
S. Savic (2010)
10.1158/0008-5472.CAN-08-4979
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
Alexandra C. Racanelli (2009)
10.1089/HUM.1998.9.7-1083
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
D. Sterman (1998)
10.1016/j.rmed.2008.03.001
A decision tree for differentiating tuberculous from malignant pleural effusions.
J. M. Porcel (2008)
Caveolin-1 is a novel
VJ Amatya (2009)
Epithelial nuclear factor - k B activation promotes urethane - induced lung carcinogenesis
A Sartore-Bianchi (2007)
Use of lipoteichoic
NM Rahman (2007)
10.1111/j.1742-4658.2009.07098.x
Onconase cytotoxicity relies on the distribution of its positive charge
Rebecca F Turcotte (2009)
10.1111/J.1445-2197.1963.TB03037.X
The classification of lung cancer.
J. D. Reid (1963)
10.1016/j.ejca.2010.02.002
A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions.
Xianhuo Wang (2010)
10.1158/1078-0432.CCR-07-0869
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
R. Hassan (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Genome-wide profile
OD Røe (2009)
Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non - small cell
K Yoshida
Opposite effects
I Graziani (2009)
10.1093/jnci/djn325
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
G. Stathopoulos (2008)
10.1097/JTO.0b013e3181cbf465
Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant Pleural Mesothelioma
C. Tan (2010)
10.1097/JTO.0b013e3181a8634d
Regression of Established AB1 Murine Mesothelioma Induced by Peritumoral Injections of CpG Oligodeoxynucleotide Either Alone or in Combination with Poly(I:C) and CD40 Ligand Plasmid DNA
G. W. Stone (2009)
10.1007/s10549-009-0602-z
Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model
I. Iankov (2009)
10.1016/j.humpath.2009.02.013
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Y. Yuan (2009)
Screening for malignant
B Grigoriu (2008)
Pro-tumorigenic effects
SV Ivanov (1916)
Nordic Mesothelioma Group
JB Sørensen (2009)
10.1097/JTO.0b013e3181c07ddc
Phase I Trial of Intrapleural Docetaxel Administered Through an Implantable Catheter in Subjects with a Malignant Pleural Effusion
D. Jones (2010)
10.1016/S1470-2045(08)70205-5
Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study.
N. Rahman (2008)
10.3109/9781420077391-16
Translational Research in Pleural Diseases
G. Stathopoulos (2010)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1111/j.1440-1843.2009.01536.x
Osteopontin is upregulated in malignant and inflammatory pleural effusions
C. Moschos (2009)
10.1371/journal.pone.0010612
Second Generation Sequencing of the Mesothelioma Tumor Genome
R. Bueno (2010)
10.1073/pnas.0813101106
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
C. Carpenito (2009)
10.1016/j.bbrc.2009.12.095
An epigenetic mechanism for capecitabine resistance in mesothelioma.
K. Kosuri (2010)
10.2147/BTT.S2383
Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
C. Porta (2008)
10.1158/0008-5472.CAN-08-1363
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.
S. Bidlingmaier (2009)
10.1183/09031936.00165607
Pleural drainage and pleurodesis: implementation of guidelines in four hospitals
J. Burgers (2008)
Demonstration of antitumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model
ID Iankov (2010)
Diagnostic accuracy of tumour
QL (2009)
10.1074/jbc.M110.100354
Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma*
S. Ivanov (2010)
10.1097/PDM.0b013e3181ba6c78
Diagnosis and Origin Determination of Malignant Pleural Effusions Through the Use of the Breast Cancer Marker Human Mammaglobin
S. Roncella (2010)
10.1164/rccm.201001-0001OC
Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.
G. Stathopoulos (2010)
10.1164/AJRCCM.162.1.9909106
A single intrapleural injection of transforming growth factor-beta(2) produces an excellent pleurodesis in rabbits.
R. Light (2000)
10.1111/j.1440-1843.2009.01663.x
Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions
J. A. Neto (2010)
10.1097/MNM.0b013e32830978c4
Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion
B. Duysinx (2008)
10.1056/NEJMC071823
11C-labeled methionine and evaluation of malignant pleural mesothelioma.
G. Ceresoli (2007)
Microfluidic sorting and
AE Saliba (2009)
Management of malignant pleural effu
J. Respir (2010)
Clinical impact and reliabil
HE Davies (2009)
10.1158/0008-5472.CAN-07-1064
Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion
G. Stathopoulos (2007)
10.1111/j.1440-1843.2009.01671.x
Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits
Y. Guo (2010)
10.1165/RCMB.2005-0130OC
Nuclear Factor-κB Affects Tumor Progression in a Mouse Model of Malignant Pleural Effusion
G. Stathopoulos (2006)
10.1183/09031936.00126306
Discrimination of exudative pleural effusions based on multiple biological parameters
Z. Daniil (2007)
10.1158/0008-5472.CAN-07-6265
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
A. Gauvrit (2008)
10.1016/J.LUNGCAN.2007.07.009
Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.
K. Yoshida (2007)
10.1002/ijc.25547
Molecular imaging of mesothelioma by detection of manganese‐superoxide dismutase activity using manganese‐enhanced magnetic resonance imaging
S. Hasegawa (2011)
10.1371/journal.pone.0007016
Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target
S. Crispi (2009)
10.1183/2312508x.erm7918
[Thoracic ultrasound].
J. Giron (2000)
10.1200/JCO.20.1.274
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
S. Mikulski (2002)
10.1016/j.ccr.2009.06.017
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
Z. Fridlender (2009)
Soluble mesothelin
P Wheatley-Price (2009)
10.1016/S1470-2045(08)70155-4
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study).
R. Lencioni (2008)
10.1158/1078-0432.CCR-09-3324
Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid
N. Dickgreber (2010)
10.1164/rccm.200909-1465OC
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
J. Hegmans (2010)
10.1158/1078-0432.CCR-08-1579
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
F. Vandermeers (2009)
10.1158/0008-5472.CAN-09-1595
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Y. Goto (2009)
Absence of mutations
V Velcheti (2008)
Guidelines of the ERS
N. Engl. J. Med (2005)
10.1016/j.radonc.2008.06.009
A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT).
M. Suzuki (2008)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)



This paper is referenced by
10.1371/journal.pone.0071207
Beneficial Impact of CCL2 and CCL12 Neutralization on Experimental Malignant Pleural Effusion
A. Marazioti (2013)
10.1164/rccm.201203-0465PP
Malignant pleural effusion: tumor-host interactions unleashed.
G. Stathopoulos (2012)
10.1007/978-94-007-4783-8_3
Diagnosis and Treatment of Malignant Pleural Effusion
Sergi Call (2012)
10.1007/s00262-015-1701-9
CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion
F. Wang (2015)
10.1515/CCLM.2011.242
Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
S. Yamada (2011)
10.1097/MCP.0b013e3283474015
Management of malignant pleural effusions
F. Rodríguez-Panadero (2011)
10.1007/s13277-016-5441-z
Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion
Q. Li (2016)
10.2217/LMT.14.21
Lung cancer coexisting with ipsilateral pleural effusion
F. Rodríguez-Panadero (2014)
10.1007/s10147-011-0368-2
Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy
S. Hasegawa (2011)
10.1186/s12967-015-0662-2
A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells
M. Acencio (2015)
Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy
Seiki HasegawaNobuyuki (2012)
10.1111/resp.12354
Staphylococcus aureus bio‐products: New biological roles for a pleurodesis agent
I. Psallidas (2014)
10.3978/j.issn.2072-1439.2015.05.20
Switching off malignant pleural effusion formation-fantasy or future?
M. Spella (2015)
10.1517/17530059.2013.786038
Current and future options for the diagnosis of malignant pleural effusion.
F. Rodríguez-Panadero (2013)
Semantic Scholar Logo Some data provided by SemanticScholar